Dr Reddys Laboratories Shares Decline Amid High Volume Trading
Despite the decline in share price during today's trading session, Dr Reddys Laboratories maintains a neutral sentiment, according to a Moneycontrol analysis as of April 29, 2025. The company's financial health, as reflected in its revenue, net profit, and key financial ratios, remains strong.
Alpha Desk
May 06, 2025 / 10:41 IST
DisclaimerThis is an AI-assisted live blog with updates sourced from multiple news outlets and agenciesDisclaimer
Dr Reddy's Share Price Today
During today's session, Dr Reddys Laboratories shares experienced a decline of 1.28 percent, with the current price at Rs 1156.50. The trading volume for Dr Reddys Laboratories witnessed a surge, drawing attention to the stock's performance.
Dr Reddys Laboratories is a constituent of the NIFTY 50 index, making its movements significant for broader market sentiment. The stock's performance is closely watched by investors, especially in light of its high trading volume today.
Financial Overview
A review of Dr Reddys Laboratories' financial performance reveals the following trends:
Revenue
The company's revenue has shown consistent growth over the past few quarters:
Dec 2023: Rs 7,236.80 Cr
Mar 2024: Rs 7,113.80 Cr
Jun 2024: Rs 7,696.10 Cr
Sep 2024: Rs 8,038.20 Cr
Dec 2024: Rs 8,381.20 Cr
Net Profit
Net profit figures have also remained robust:
Dec 2023: Rs 1,378.20 Cr
Mar 2024: Rs 1,306.30 Cr
Jun 2024: Rs 1,386.50 Cr
Sep 2024: Rs 1,335.80 Cr
Dec 2024: Rs 1,400.00 Cr
Earnings Per Share (EPS)
The EPS figures indicate the company's profitability on a per-share basis:
Dec 2023: 82.94
Mar 2024: 78.66
Jun 2024: 83.61
Sep 2024: 80.45
Dec 2024: 16.97
Annual Financial Highlights
Looking at the annual performance, Dr Reddys Laboratories has demonstrated substantial growth:
Revenue: Increased from Rs 17,517.00 Cr in 2020 to Rs 28,011.10 Cr in 2024.
Net Profit: Rose from Rs 1,969.90 Cr in 2020 to Rs 5,563.20 Cr in 2024.
EPS: Climbed from 122.22 in 2020 to 335.22 in 2024.
BVPS: Increased from 938.56 in 2020 to 1,693.93 in 2024.
ROE: Showed strong returns, from 12.98 in 2020 to 19.74 in 2024.
Debt to Equity: Remained relatively stable, with 0.11 in 2020 and 0.06 in 2024.
Cash Flow and Balance Sheet
The company's cash flow from operating activities was Rs 4,543 Cr in March 2024. The total assets stood at Rs 38,863 Cr, with fixed assets at Rs 11,294 Cr and current assets at Rs 24,805 Cr.
Key Financial Ratios (Mar 2024)
Ratio
Value
Basic EPS (Rs.)
335.22
Diluted Eps (Rs.)
334.59
Book Value / Share (Rs.)
1,693.93
Dividend/Share (Rs.)
40.00
Gross Profit Margin (%)
31.51
Operating Margin (%)
26.26
Net Profit Margin (%)
19.86
Return on Equity (%)
19.74
ROCE (%)
25.13
Return On Assets (%)
14.35
Debt to Equity (x)
0.06
Interest Coverage Ratios (X)
51.59
P/E (x)
3.67
P/B (x)
3.63
EV/EBITDA (x)
11.62
P/S (x)
3.67
Despite the decline in share price during today's trading session, Dr Reddys Laboratories maintains a neutral sentiment, according to a Moneycontrol analysis as of April 29, 2025. The company's financial health, as reflected in its revenue, net profit, and key financial ratios, remains strong.
